Combined 70- and 80-gene signatures identify tumors with genomically luminal biology responsive to neoadjuvant endocrine therapy and are prognostic of 5-year outcome in early-stage breast cancer.
Pellicane JV, Beitsch PD, Rock DT, Budway RJ, Dul CL, Kelemen PR, Ashikari AY, Baron PL, Weinstein PD, Mislowsky A, Lee LA, Beatty J, Murray MK, Dupree BB, Finn C, Corcoran K, Wang S, Menicucci AR, Yoder EB, Blumencranz LE, Dauer P, Audeh W, Whitworth PW; NBRST Investigators Group.
Pellicane JV, et al. Among authors: whitworth pw.
Surg Oncol. 2022 Dec;45:101885. doi: 10.1016/j.suronc.2022.101885. Epub 2022 Nov 22.
Surg Oncol. 2022.
PMID: 36436423
Free article.